Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50

Judge Halts Alzheimer’s Drug Swap Until July

By Drug Discovery Trends Editor | December 16, 2014

A federal judge on Monday ordered an Irish drug manufacturer to halt its plans to discontinue its widely used Alzheimer’s medication, allegedly in an effort to drive patients to a newer patented drug.
 
U.S. District Judge Robert Sweet told Dublin-based Actavis PLC to continue making the drug Namenda available for 30 days after generic alternatives become available on July 11 “in order to allow for an orderly transition.”
 
His injunction orders the company to inform doctors and pharmacists of the decision and tells Actavis not to impose any hurdles for filling prescriptions of the drug.
 
Actavis said it will appeal Monday’s ruling. The company said its new drug Namenda XR – taken once daily instead of twice – is better and demand is growing.
 
The ruling will have “no impact on its ability to continue focusing its resources on transitioning patients” to the new drug, Actavis said. It is “prepared to manage its business in a way that provides the least disruption in its ability to support the marketplace and minimize any financial impact.”
 
New York Attorney General Eric Schneiderman sought the court order. He alleged that Actavis and New York subsidiary Forest Laboratories violated anti-trust and state laws in an effort to avoid losses from cheaper generic alternatives coming out next year.
 
“Unfortunately, schemes to block competition, without considering the consequences to patients, are a growing trend in the health care industry,” Schneiderman said when he filed the lawsuit in September. His office is looking at other drugs and companies.

Filed Under: Drug Discovery

 

Related Articles Read More >

Takeda Pharmaceutical in the Drug Discovery & Development Pharma 50
Takeda’s Takhzyro fares well in pediatric hereditary angioedema study
Novartis in the Pharma 50
Novartis to cut up to 8,000 positions
Gilead Sciences in the Drug Discovery & Development Pharma 50
Gilead resubmits application to FDA for twice-yearly HIV drug lenacapavir
George Floyd mural
How the pandemic and George Floyd made clinical trial diversity a priority

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50